| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CSK |
| Uniprot No | P41240 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-450aa |
| 氨基酸序列 | SAIQAAWPS GTECIAKYNF HGTAEQDLPF CKGDVLTIVA VTKDPNWYKA KNKVGREGII PANYVQKREG VKAGTKLSLM PWFHGKITRE QAERLLYPPE TGLFLVREST NYPGDYTLCV SCDGKVEHYR IMYHASKLSI DEEVYFENLM QLVEHYTSDA DGLCTRLIKP KVMEGTVAAQ DEFYRSGWAL NMKELKLLQT IGKGEFGDVM LGDYRGNKVA VKCIKNDATA QAFLAEASVM TQLRHSNLVQ LLGVIVEEKG GLYIVTEYMA KGSLVDYLRS RGRSVLGGDC LLKFSLDVCE AMEYLEGNNF VHRDLAARNV LVSEDNVAKV SDFGLTKEAS STQDTGKLPV KWTAPEALRE KKFSTKSDVW SFGILLWEIY SFGRVPYPRI PLKDVVPRVE KGYKMDAPDG CPPAVYEVMK NCWHLDAAMR PSFLQLREQL EHIKTHELHL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CSK(C-terminal Src kinase)重组蛋白相关的文献摘要信息，供参考：
---
1. **文献名称**：*Crystal Structure of Human CSK Reveals Autoinhibitory Mechanism*
**作者**：Yamaguchi, H., Hendrickson, W.A.
**摘要**：通过重组表达人源CSK蛋白并解析其晶体结构，揭示了其激酶结构域的自抑制机制。研究表明，CSK的SH2和SH3结构域通过空间位阻抑制激酶活性，为靶向CSK的抑制剂设计提供结构基础。
---
2. **文献名称**：*Regulation of Src Family Kinases by CSK in Immune Signaling*
**作者**：Okada, M., Nada, S.
**摘要**：利用重组CSK蛋白进行体外磷酸化实验，证明CSK通过磷酸化Src家族激酶(如Lck和Fyn)的C端酪氨酸残基，负调控其活性，从而影响T细胞受体信号传导通路。
---
3. **文献名称**：*Expression and Functional Analysis of Recombinant CSK in Cancer Cells*
**作者**：Howell, B.W., Cooper, J.A.
**摘要**：通过大肠杆菌系统重组表达并纯化CSK蛋白，研究其在癌细胞迁移中的作用。实验表明，重组CSK可通过抑制Src活性降低癌细胞侵袭能力，提示其潜在抗肿瘤应用。
---
4. **文献名称**：*CSK Homology Domain Interactions Studied by Surface Plasmon Resonance*
**作者**：Hrdlicková, R., et al.
**摘要**：利用表面等离子体共振技术(SPR)分析重组CSK蛋白与SH3结构域配体的相互作用，揭示其结合动力学参数，阐明CSK在细胞骨架重组中的分子机制。
---
**注意**：以上文献为示例性质，具体内容需通过PubMed或Web of Science等学术平台检索确认。如需全文，建议使用关键词“C-terminal Src kinase recombinant”或“CSK protein expression”进行精准查询。
**Background of CSK Recombinant Protein**
C-terminal Src kinase (CSK) is a non-receptor tyrosine kinase that plays a critical role in regulating the activity of Src family kinases (SFKs), a group of signaling proteins involved in cell proliferation, differentiation, migration, and survival. CSK acts as a key negative regulator by phosphorylating a conserved inhibitory tyrosine residue in the C-terminal tail of SFKs, thereby suppressing their enzymatic activity. Dysregulation of CSK-SFK signaling is associated with various pathological conditions, including cancer, immune disorders, and inflammatory diseases.
Recombinant CSK protein is engineered using genetic expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional CSK for research and therapeutic applications. Its recombinant form retains the native structure and enzymatic activity, enabling studies on SFK regulation, signal transduction pathways, and drug discovery. CSK recombinant proteins are often tagged with affinity markers (e.g., GST, His-tag) to facilitate purification and detection.
In biomedical research, recombinant CSK is widely used to investigate mechanisms underlying T-cell receptor signaling, cytoskeletal dynamics, and oncogenic pathways. It also serves as a tool for screening inhibitors targeting SFK-related diseases. Additionally, studies leverage CSK knockout models and recombinant protein rescue experiments to dissect its physiological roles.
Overall, CSK recombinant protein is a vital reagent for advancing our understanding of tyrosine kinase networks and developing targeted therapies for SFK-driven disorders. Its applications span basic molecular biology, translational research, and pharmaceutical development.
×
